20 July 2026
20 July 2026
Completion of the deal is anticipated towards the end of 2026.
While UK biotech financing recovery is present in the private markets, BIA CEO Chris Molloy notes that UK public sector backing is essential for sustained growth.
The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.
The framework combines Aptar Pharma’s elastomeric experience and a network of partners across the injectable drugs sector.
Kerendia will become available to English patients with chronic heart failure with preserved or mildly reduced ejection fraction.
The JCVI review incorporated recent data on the effectiveness in adolescents vaccinated against MenB in infancy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
